

# Measles and Rubella Serosusceptibility among Population Vaccinated with Different Schedule: The potential impact on Measles-Rubella elimination in Iran.

**Hana Saffar**

Department of antimicrobial and clinical Pathology, IKHC, Teheran University of Medical Sciences, Tehran Iran.

**Maryam Khalifelo**

The University of Manchester Faculty of Biology Medicine and Health

**mohammed-Jafar Saffar** (✉ [saffar@softhome.net](mailto:saffar@softhome.net))

Mazandaran University of Medical Sciences <https://orcid.org/0000-0002-9335-6262>

**Ali-Reza Abdollahi**

Department of antimicrobial and clinical Pathology, IKHC, Teheran University of Medical Sciences, Tehran Iran.

**Mohammad-Reza Parsaei**

Deputy of Health, Mazandaran University of Medical Sciences.

**Gholam-Reza Ghorbani**

Deputy of Health, Mazandaran University of Medical Sciences.

**Samaneh Salarvand**

Department of antimicrobial and clinical Pathology, IKHC, Teheran University of Medical Sciences.

**Mohsen Aarabi**

Deputy of Health, Mazandaran University of Medical Sciences.

---

## Research article

**Keywords:** Measles, Rubella, MMR, Measles elimination, congenial rubella syndrome. Iran.

**Posted Date:** January 4th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-40094/v3>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

**Version of Record:** A version of this preprint was published on March 25th, 2021. See the published version at <https://doi.org/10.1186/s12879-021-05970-7>.

## Abstract

**Background:** Iranian children have been vaccinated with the scheduled two doses of monovalent measles vaccine (mMV) since 1984. In December 2003, a nationwide campaign of measles-rubella (MR) immunization targeted 5-25 years population was established. In 2004, the mMV was replaced with measles-mumps-rubella (MMR) vaccine. Despite the high vaccination coverage, the outbreaks of measles still occurs in the country. In this Study, the measles-rubella immunity status of various age groups, vaccinated with different schedules was investigated, and the immunologic response of seronegative subjects to revaccination was examined.

**Methods:** This cross-sectional study was conducted among 7-33-year-old healthy individuals with a documented history of measles vaccination from November 2017-to June 2018. The subjects were categorized as follow: groupA: including 20-33 years-old; vaccinated with 1-2 dose of mMV, and revaccinated with MR, groupB, including 15-19-year-old individuals, vaccinated with two doses of mMV at nine and 15 months of age, and in addition to one dose MMR upon school entrance, groupC, including 11-14 year-old individuals vaccinated, with two-doses of MMR at the ages of 15 months and six years, and groupD, including 7-10 year individuals vaccinated with two-doses of MMR vaccine at the ages 12 and 18 months, respectively. Next the concentrations of antimeasles-antirubella IgG antibodies in the collected sera were measured. Among seronegative subjects, the antimeasles-antirubella IgM and IgG were reexamined at 4-6 weeks after MMR revaccination. The collected data were analyzed using descriptive statistical methods.

**Results:** A total of 635 individuals, including 322 females were investigated in this study. The relative distribution of subjects in each group was as follows: groupA, 98; groupB, 295; groupC, 139; and groupD, 103 persons. Overall, 12.3% and 18.4% of the population were seronegative for measles and rubella antibodies. This rate varied greatly between the 4 groups: groupA, 2%-0/0%; groupB, 15.2%- 25.0%; groupC, 11.5%- 17.2%; and groupD, 14.6%- 18.4%. After revaccination, 92% and 94.9% of seronegative individuals only showed IgG response to measles and rubella vaccines, respectively.

**Conclusion:** Despite the high coverage rate of M-R containing vaccines, a significant numbers of vaccinated subjects were seronegative for measles and rubella, possibly because of secondary vaccine failure; this may negatively affect measles-rubella elimination targets in the country. If these findings are confirmed in similar future studies, a more robust regional/national supplementary immunization activity should be considered.

## Background

Measles, a highly contagious viral disease, recognized as a major public health concern worldwide<sup>(1)</sup>. In 2018, there were more than 140/000 measles-related death globally, mostly among children under the age of 5 years<sup>(2)</sup>. Age of vaccination is one of the key host-related determinants of vaccine efficacy (VE). However, results of previous studies have revealed that measles vaccination at the age < 12 months is associated with the reduced immune response rate because the interference of maternal antibodies and immaturity of the immune system<sup>(3-5)</sup>. To prevent the measles virus transmission in a community, a population immunity rate of > 93- 95% with > 95% vaccination coverage (with two-doses of vaccine) is required in all districts of the country<sup>(1,6)</sup>. In recent years, the number of measles cases and its outbreaks have started to increase, even in countries declaration disease elimination, also, some of these cases have been reported in fully vaccinated individuals<sup>(7-16)</sup>. From January- to July 31 2019, a total of 364, 808 measles cases were reported to World Health Organization (WHO) by 182 countries, which surpasses the number of reported cases (129. 239) within the same period in 2018<sup>(7)</sup>.

On the other hand, rubella a mild viral infection that affects unvaccinated children and adults. If a nonimmune women contracts rubella during pregnancy, especially in the first trimester, serious consequences including miscarriage, fetal death, stillbirth and congenital rubella syndrome (CRS) may occur. Nonetheless, CRS is a vaccine-preventable congenital anomaly<sup>(17)</sup>.

During the pre-vaccine era in Iran, measles and rubella were endemic and nearly 150,000- 500,000 cases of measles with a high mortality rate were reported annually<sup>(18-19)</sup>. However, more than three-fourth of adolescents and childbearing age women naturally acquired anti-rubella immunity<sup>(20-21)</sup>, and the incidence of CRS was estimated to be two per 10,000 live birth<sup>(22)</sup>. Following the establishment of the WHO Expanded Program of Immunization (EPI) in Iran in 1984, the incidence of measles cases reduced markedly. However, in response to the increased number of measles cases particularly in older age groups, a nationwide measles- rubella (MR) immunization campaign targeting 5- 25 year-old individuals was established in December 2003 to prevent CRS<sup>(23)</sup>.

After the mass MR immunization program, many seroprevalence studies results revealed that nearly 63.2% - 92% and 87- 99% of vaccinees acquired seroprotection against measles and rubella respectively<sup>(24-29)</sup>.

Since March 2004, the mMV was replaced with two-doses of measles-mumps-rubella (MMR) vaccine, scheduled after the age of 12 months, with more than 95% coverage rate<sup>(23,30)</sup>. This shift in the program led to the accumulation of a birth cohort born between November 1998 to March 2004, who were vaccinated with two- doses of mMV at the age of nine and 15 months respectively. However, to provide protection against mumps and rubella, this particular groups was revaccinated with one dose of MMR vaccine at the time of school entrance (2 to 5 years after the last dose of mMV).

In 2019, WHO Region Verification Committee of the Eastern Mediterranean region declared the elimination of the measles and rubella in Iran<sup>(31)</sup>. However, in recent years, small outbreaks of measles have been reported in some parts of the country<sup>(12-16)</sup> Table 1. The measles virus causing these outbreaks was reported to originate from neighbor countries<sup>(16,32)</sup>.

**Table 1.** Measles outbreaks reported in Iran Since 2006 to 2016. 2-14 years after the MR campaign and the onset of two-doses MMR immunization program.

Author/ reported province	Years of outbreaks	No of cases	Involved age groups	vaccination status
Nejati J, et al/ Sistan-Bluchestan <sup>12</sup>	2006-11	456 cases	All age groups: 48% in <5 yrs 34% in 5-9 yrs	One dose: 11.2% 2-dose: 27.8%, not vaccinated: 55.1%
Izadi s southeast of Iran <sup>13</sup>	2009-10	126 cases (2 main outbreaks)	All age groups 42% ≥ 7 yrs 6.3% >20 yrs	2-dose vaccine efficacy =74.2%
Moghaddam <sup>14</sup> Fars	2012	7 cases	11mo - 35 yr	2-dose: 3case, Non-vaccinated: 2 cases
Karami M <sup>15</sup> National level	2012-2014	2012:232 cases 2014: 142 cases	All age groups	22.7%: <12 mo 19.3%: vaccinated 36.5%: non-vaccinated
Piri N <sup>16</sup> National level	2014-2016	759 cases	31.1%: <1 yr 13.2%: 1-4 y	20.4% <12 mo 23.3%: vaccinated

There is little Information available regarding level of measles and rubella protection among children, adolescents and adults vaccinated with different schedules. Therefore, this study was designed to investigate the prevalence rates of measles and rubella immunity among various age groups that were vaccinated with different programs, and also to determine the relative role of secondary vaccine failure as a possible cause of serosusceptibility to viruses.

## Methods And Participants

This descriptive-analytical cross-sectional study was conducted in the East of Mazandaran province, North of Iran, from 1-November 2017 to 30-June 2018. This region is consists of three main districts with an approximate population of 460000. Depending on the population density of each district, some primary health care centers (PHCs) have been established. All basic health requirements including prenatal care and vaccination of children in the affiliated families are met in these centers. Also, each family has a specific file where all health related events of that family are recorded there.

To collect the data, the family files available in each PHC were thoroughly reviewed. Healthy subjects born during 1984-2011 with a documented history of measles vaccination were recruited in the study. The subjects required for this study were selected among eligible individuals, based on the population density of PHC by one to one selection method. Since the majority of selected cases were students (primary and high school students), their vaccination status was rechecked from a copy of their booklet record which was present in their school file. History of MR vaccination in some adults was based on their recall.

Individuals with acute diseases, history of recent febrile exanthematous illnesses, chronic and metabolic illnesses, malignancies, immunodeficiency, recipients of blood/ blood products within last year, recipient of an additional dose of measles containing vaccine after the recommended schedule (except those who received MR vaccine during nationwide measles-rubella campaign recipients of MMR vaccine at school entrance among birth cohort 1998-2003), and pregnant women were all excluded from the study.

Depending on age and vaccination status, the subjects were categorized as follows; Group A: the subjects were born 1984 to October 1998, (age range: 20- 33 years). Most of them were vaccinated with 1-2 doses of measles vaccine at the ages of nine and 15 months and were also reimmunized with MR vaccine during the national MR Immunization campaign. Overall, they were vaccinated with three doses of measles and one dose of rubella vaccine. Group B: the subjects were born from November 1998 to March 2004 (age range: 15-19 years). This birth cohort was vaccinated with two doses of mMV at the ages of nine and 15 months, respectively. They were also reimmunized with additional dose of MMR vaccine of school entrance (age of 6 years); therefore, they received three doses for measles and one dose for rubella and mumps vaccine.

Group C: The subjects were vaccinated from March 2004 to March 2007 (Age range: 11-14 years). They were vaccinated with two doses of MMR vaccine at the age of 12- 15 months and 6 years, respectively. Group D: the subjects were vaccinated from April 2008 to the end of year 2011 (Age range 7-10 years) with two-doses of MMR at the ages of 12 and 18 months. The group characteristics are presented in Table 2.

**Table 2:** Demographic characteristics of studied population based on age, vaccination status, and time elapsed since receiving the last vaccine dose, in the East of Mazandaran, North of Iran.

studied groups variable	A	B <sup>d</sup>	C	D <sup>f</sup>	Total
No of subjects	98	295	139	103	635
Age range yr	20-33	15-19	11-14	7-10	7-33
(Date of birth)	1984-1998	1999-2003	2004-2007	2008-2011	1984-2011
Female/male ratio	59/39	139/156	75/64	49/54	322/313
Year and time elapsed since the last dose of vaccination	2003 /15 yr	2004-7/ 13-15 yr	2004-7/ 10-13 yr	2008-11/ 7-10 yr	-
history of MV <sub>1</sub> and MV <sub>2</sub> <sup>a</sup>	+	+	-	-	-
History of MR <sup>b</sup>	+	-	-	-	-
History of MMR <sup>c</sup>	No	One dose	2-doses	2-doses	-

- a: MV<sub>1,2</sub> measles vaccine first dose, second dose.
- b: MR: measles-rubella vaccine.
- c: MMR measles-mumps-rubella vaccine.
- d: GB: this group, in addition to receipt two dose of MV at the age 9 and 15 months, with one dose of MMR vaccine at time of school entrance were immunized.
- e: This group with two–doses of MMR vaccine at the age 12-15 months and 6 years were immunized.
- f: This group with two–doses of MMR vaccine at the age of 12 and 18 months were vaccinated.

Standard protocols and ethical guidelines were used and the study was approved by the Ethic committee of Mazandaran and Tehran Universities of Medical Science: IR.MAZUMS. Rec.1396.3074 and Tehran IR.TUMS.IKHC. Rec.1399.075, respectively.

After obtaining informed written consent from guardians/ individuals, 5 ml of venous blood of all enrolled subjects were collected. Sera were stored at- 20°C to measure anti-measles and anti-rubella IgG antibodies qualitatively at the university laboratory by ELISA method using Vircell Microbiologic ELISA measles and rubella IgG/IgM kits (vircell, S. L. parquet Tecnologico dela salud. Avecina 8. 18016 Granada. Spain). Antibodies against measles and rubella were measured based on manufacture's guidelines. The results were interpreted as antibody indices. The samples antibody indices were calculated with positive and negative control (OD >0.9 and OD < 0.5) at a control cut-off range of >0.55 to <1.5. Samples antibodies indexes were calculated as: (Sample OD/cut-off serum mean OD)×10. Samples with antibody index above 11 were considered as positive (having specific measles IgG/IgM per procedure). Samples with antibody index less than 9 were considered as negative. Subjects with index between 9-11 were rechecked and if reported >11 were considered positive and if <11 as negative. Similar categorization were applied for rubella. Nevertheless rubella ELISA IgG has been standardized against WHO first international standard for antirubella IgG with a cut-off set at 10 UI/mL. Based on the manufacture

*sepr or ts, whi ≤ comparedwithothercommercialELISAspec if ickits, thesensitivity and spec if icityofkitf or meas ≤ sIgGwere92 - 100*

sera tested for measles and rubella specific IgM and IgG. Subjects with both IgM and IgG seroconversion were considered as cases of primary vaccine failure [possibly never develop immune response to the initial vaccination: (PVF)]. Subjects with only IgG seroconversion were considered as secondary vaccine failure [loss of acquired specific antibody with time (SVF)]. MCAs of seropositive individuals were calculated after boosting, and were compared with the previous level. The collected data were analyzed using SPSS version 16.0. Descriptive statistics were measured as percentile for seropositivity and response rate to revaccination. The chi-square and student t-test were used to determine differences between variables as appropriate. Results were considered to be statistically significant when the P value was less than 0.05.

## Results

A total of 635 individuals participated in this study. The demographic characteristics and vaccination status of the participants are presented in Table 2.

Of 635 studied subjects 78 (12.3%) and 117(18.4%) were serologically susceptible to measles and rubella respectively. The prevalence rates of measles and rubella susceptibility in different age groups varied significantly, as shown in table 3. The highest rates of susceptibility to measles and rubella were seen in the group D (15.2% and 25.0% respectively), followed by the group D (14.6% and 18.4%, respectively).the highest seroprotection rate (98% and 100%) were

observed in oldest subjects, who were MR revaccinated. However, comparison of the prevalence rates of measles and rubella seroimmunity between the groups showed significant differences between group A and other groups: ( $P=0.000$ ). Also, there were significant differences in the measles MCA between group A and group B ( $P=0.006$ ) and between group A and group C ( $P=0.001$ ). Similarly significant differences were observed in rubella MCA between group A and group D ( $P=0.013$ ) and between group C and group D ( $P=0.031$ ).

After revaccination of 171 susceptible cases (measles 78 and rubella 117), only 71 subjects (measles 50 and rubella 59) agreed to blood sample collection for reevaluation. As shown in table 3, 92% and 94.9% of revaccinated seronegative persons responded well to MMR vaccine boosting and became IgG-seroconverted against measles and rubella, respectively. None of the boosted subjects showed evidence of antimeasles or antirubella IgM response; therefore, seronegativity was possibly caused by loss of acquired immunity over time and SVF. The MCA levels of seroimmune individuals for both measles and rubella were not statistically significant after revaccination as compared to MCA levels in the primary evaluation: for measles 18.35 vs 20.06  $P=0.149$ , rubella; 22.63 vs 22.03,  $P=0.603$ .

**Table 3.** Measles and rubella immunity status among different age groups population vaccinated with various vaccination schedule and their response to revaccination, East of Mazandaran province, North of Iran.

Groups (n) birth date	GA: n=98 1984-1998	GB: n=295 1999-2003	GC <sup>1</sup> : n=139 2004-2007	GD <sup>1</sup> : n=103 2008-2011	Total n=635 1984-2011
vaccination status:	A	B	C	D	
mMV:	+	+	-	-	different schedule
MR:	+	-	-	-	
MMR:	-	+ one dose	+ 2-doses	+ 2-doses	
Measles :					
Seroimmune n(%)	96 (98%)	250 (84.7%)	123 (88.5%)	88 (85.4%)	557 (87.7%)
MCA±SD	25.15±6.47	17.63±7.21	19.34±7.02	17.17±7.42	19.19±7.59
Response rate to revaccination responders/total(%)	-	26/28(92.8%)	11/12(91.6%)	9/10(90%)	46/50(92%)
Rubella:					
Seroimmune: n(%)	98(100%)	221(74.9%)	115(82.9%)	84(81.55%)	518(81.57%)
MCA±SD	25.71±2.29	23.07±15.56	24.67±12.51	20.09±9.83	23.36±13.14
Response rate to revaccination responders/ total(%)	-	34/36(94.4%)	15/16(93.7%)	7/7(100%)	56/59(94.3%)

mMV: monovalent measles vaccine, MMR: measles-mumps-rubella vaccine, MR: measles rubella vaccine, yr: year, Mo: month, MCA: mean concentrations of antibody.

1: these 2 groups (C&D) that were vaccinated with 2-dose of MMR vaccine after the age of 12 months: 16+15=31 (12.8%) and 24+19=43(17.7%) were susceptible to measles and rubella respectively.

## Discussion

This study showed that more than 12% and 18% of the studied individuals were serologically susceptible to measles and rubella, respectively. The highest rates of susceptibility to measles and rubella (15.2% and 25% respectively) were observed among subjects in group B (15- 19 year old) who were born within 5 years before national MR immunization program and were vaccinated initially with two doses of mMV at the ages nine and 15 months, respectively. Two to five years later, they also received an additional dose of MMR vaccine right before entrance to school (age of 6 years). Moreover, the present results showed that 12.8% and 17.7% of subjects who were vaccinated with two doses of MMR vaccine after the age of 12 months (group C and group D), were serologically susceptible to measles and rubella, respectively. In this study the lowest rate of serosusceptibility to measles and rubella was detected among 20- 33- year- old adults who were MR revaccinated. Based on our findings, the main possible cause of susceptibility to measles and rubella in our vaccinated population was waning of acquired seroprotection with time (SVF), because of isolated IgG immunologic response to MMR revaccination in boosted susceptible individuals. Moreover, the results revealed that the levels of acquired MCA after revaccination of seroimmune subjects for both measles and rubella with MMR vaccine, did not improved specific immunity to these viruses.

The present result showed that 98% and 100% of subjects in group A (age 20-33 years) who were covered by the national program of MR immunization were serologically immune to measles and rubella, respectively. The long- term high- rate of protection could be attributed to MR vaccination or natural boosting in

Loading [MathJax]/jax/output/CommonHTML/fonts/TeX/fontdata.js seroprevalence rates in the Iranian population were much lower<sup>(33-37)</sup> (40.7%<sup>33</sup> - to 91.6%<sup>37</sup>) than the

rates reported in this study. However, studies performed years after revaccination in different age groups indicated much higher levels of seroprotection: (63.2<sup>(29)</sup>% to 91.7<sup>(28)</sup>% for measles and 87.4<sup>(28)</sup>% to 99<sup>(24)</sup>% for rubella)<sup>(24-29)</sup>. The relevant data are presented in Table 4. In a recent nationwide study conducted 13-14 years after the national MR campaign on girls above 15 years, the seroprotection rates to measles and rubella were investigated. Nearly 1573 sera were included from ten different provinces. The seroimmunity rates to measles and rubella were 80.7% (range 73.1%- to 89.8%) and 90.6% (range; 81.2- 95%) respectively <sup>(38)</sup>. However, these rates varied greatly between provinces. The relatively high rate of seroprotection observed in our study as well as the mentioned studies, which were conducted years after national campaign could be attributed to the positive impact of MR revaccination and/or natural boosting in the immunized population.

**Table 4.** Measles and Rubella seroprevalence rates demonstrated in different studies before and after the MR campaign in Iran.

Author/province	Relation to 2003 MR campaign	Years of study	No of Subjects (Age-groups)	Tested method	Prevalence Rate	
					Measles	Rubella
Emami-Naeini, Shiraz <sup>33</sup>	Before 3-yr	2000	241 (19-25 yr)	ELISA	40.7%	
Yekta, Uremia <sup>34</sup>	Before (1- yr)	2002	835 (5-25 yr)	ELISA	54.7%	-
Saffar, Sari <sup>35</sup>	Before (1- yr)	2002	590(15-25yr)	ELISA	55.4%	-
Zamani, Tehran <sup>36</sup>	Before (2- yr)	2001	1665 (6-11yr)	ELISA	72%	-
Salimi, Tabriz <sup>37</sup>	Before (1- yr)	2002	225 (5-25 yr)	HI test	91.6%	-
Pourabbas, Shiraz <sup>24</sup>	After (1- yr)	2004-5	909(6-26yr)	ELISA	80.6% - 87.5%	91.0%-99%
Yekta, Uremia <sup>25</sup>	After (1- yr)	2004	624 (6-25yr)	ELISA	72.3%	-
Honarvar, Shiraz <sup>26</sup>	After (7- yr)	2010-11	175 (16-24yr)	ELISA	81.7%	96%
Keshavarz, Tehran <sup>27</sup>	After (10- yr)	2014	53 (19-26 yr)	ELISA	79.2%	96.2%
Izadi, Bluchestan <sup>28</sup>	After (12-13- yr)	2015	1056 (16-20 yr)	ELISA	91.7%	87.4%
Karami, Hamadan <sup>29</sup>	After (13- yr)	2016	272 (1-40 yr)	ELISA	63.2%	-

Yr: year, mo: months

In this study, the highest rate of measles and rubella susceptibility was observed in subjects of group B (age range: 15- 19 years), who were vaccinated not only with two- doses of mMV at the ages of nine and 15 months, but also received an additional dose of MMR vaccine upon school entrance (three doses of measles and one dose of rubella vaccine). These seronegativity to MR viruses in this age group detected nearly 13-15 years after the last dose of MMR vaccine, are unusual and raise some concern. Since, there is no information about immune responses to the primary measles immunization in this age group, the actual reasons for this rate of susceptibility and vaccine failure is unclear. However, waning of acquired seroimmunity over time may be influential, as the majority of boosted susceptible subjects in this group only showed IgG response to MMR revaccination.

The quality and durability of measles vaccine-induced immunity are dependent on a number of factors including the host and the vaccine status. The most important and well-studied host-related determinant is the age when the first dose of vaccine is administered<sup>(3-5,39)</sup>. Studies on the immunogenicity and VE of MV administered before the age of 12 months, showed lower rates as compared to older ages<sup>(3-5, 39)</sup>. In this regard, a prospective randomized trial by Redd et al<sup>(3)</sup>, investigated the immunogenicity of measles component of MMR vaccine administered at the ages 9,12, and 15-18 months. They found a 98% seroconversion rate among 15 month-old vaccinees as compared to 95% in those vaccinated at the age of 12 months and 81% in those vaccinated at the age nine months<sup>(3)</sup>. Moreover, a study by Perez et al<sup>(4)</sup> revealed that measles vaccination at the age of < 12 months was associated with a higher risk of PVF. This negative effect persisted after vaccination with the second dose<sup>(4)</sup>. These results were confirmed supported by a recent systematic reviews and meta-analysis<sup>(5, 39)</sup>. Moreover, to determine the effects of age on the immunogenicity of measles vaccine a systematic review was recently performed. This study showed that earlier age of vaccination decreased the measles vaccine immunogenicity and protection after the first dose, and could influence VE after administering two-doses measles vaccine<sup>(39)</sup>. However, in another review by Uzicanin et al<sup>(5)</sup> estimating the measles VE, they found that two-dose measles vaccine provide excellent protection. Nevertheless, in three out of eighth studies, VE was estimated at <90% relative to no vaccination<sup>(5)</sup>.

On the other hand, some evidence suggests that antibody concentrations decline to low or undetectable levels over time<sup>(40-44)</sup>. In this regard a study was conducted on different age groups of Iranian children who were vaccinated against measles at the age of nine and 15 months. The seroimmunity rates were 52.9% and 89.2% at five and three months after administering the first and second doses of MV, respectively. These rates decreased to 68% by the age six years and 40.5% by the age ten years. However, the seroimmunity rates increased to 96.8% at nine months after boosting with one dose of MV at the age of 14 years<sup>(40)</sup>. Moreover, in a longitudinal study by Kremer et al<sup>(41)</sup>, on the kinetic of measles and rubella antibodies, both antibodies waned over time, also, the rate of waning immunity was relatively faster for measles<sup>(41)</sup>. Considering, the relatively high rates of measles and rubella susceptibility in group B in our study, this seronegativity could be attributed to both primary and secondary vaccine failure. To determine whether the seronegativity is related to PFV or SVF, there are two methods of assessment. These methods include IgG avidity test and IgM response to revaccination. In this study we used the IgM method, and found nobody positive response. These negative results are probably due to SVF. Possible delay in blood sampling for IgM detection and the lower sensitivity of the assay may be also influential. Nevertheless, this finding is most probably associated with SVF, due to isolated IgG seroconversion in boosted seronegative subjects.

The results of most study from developed countries have shown that approximately 90- 95% of children vaccinated at the age of <sup>3</sup>12 months produce sufficient specific antibodies against measles and rubella. The protection rates will increase up to 95- 98% after the second dose vaccination and persist for decades<sup>(1,3-6)</sup>, although some studies have shown that the achieved seroprotection rate may decline over time or years after the initial immunization <sup>(42-44)</sup>. In this study, nearly 12.8% and 17.7% of 7- 15-year-old subjects in group C and D (vaccinated with two doses of MMR vaccine administered after the age of 12 months) were serologically susceptible to measles and rubella, respectively, however, the exact cause of this lower unexpected rate is unknown. After revaccination, nearly all boosted serosusceptible subjects develop isolated IgG antibody response without IgM, and showed evidence of secondary immune response, besides waning of acquired immunity over time. Nevertheless, the present study waning of measles and rubella seroprotection rates after the primary vaccination occurred relatively earlier than expected time <sup>(1,5,6,39)</sup>. Loss of acquired immunity after vaccination, particularly within a shorter period than expected time, is of concern<sup>(45,46)</sup>. Therefore, vaccine- related factors such as lack of adequate potency of vaccine because of using more thermolabile strains, inadequate control of cold chain shipment/storage/ and use, and other probable factors may be responsible <sup>(45-47)</sup>. Our assumption regarding the inadequate potency of vaccine is based on the results of studies that were designed to investigate the immunogenicity of MMR vaccine currently in used in Iran<sup>(48-53)</sup>. The majority of these studies showed lower rates of seroconversion following the first and/or the second doses of MMR vaccine after the age of 12 months (Table 5).

**Table 5.** Immunogenicity and seroconversion rates to measles and rubella components of MMR vaccine currently in used in Iran.

Author/province vaccine brand	Years of study	No of Subjects	Age	Lab method	Responses Rate MMR (%)			
					MMR <sup>1</sup>		MMR <sup>2</sup>	
					M	R	M	R
Saffar, Mazandaran Razi-Iran <sup>48</sup>	2007	112	12.10 mo	ELISA	84.8%	53%	-	-
Saffar, Mazandaran Razi-Iran <sup>49</sup>	2011	249	18m	ELISA	74%	75%	94.4%	92.6%
					6mo after MMR1		1- mo after MMR2	
		228	6 yr		78.9%	66%	98.2	87%
					5 yr after MMR1		1- mo after MMR2	
Shamsizadeh, Ahwaz Karaj-Iran Razi Iran <sup>50</sup>	2010-	70	18 mo	ELISA	42.9%	90%	-	-
	2011	90	6.5 yr <sup>a</sup>		6mo after MMR1	-	45.6%	87.8% <sup>a</sup>
Tabatabaei, Razi-Iran <sup>51</sup>	2011- 2012	240	13.27 mo (12-15)	ELISA	75.8%	73.8%	-	-
Zahraei, Bluchestan Kerman-Hormozgan Razi-Iran <sup>16</sup>	2016	236	>12 mo	ELISA	91.2% <sup>b</sup>	-	-	-
Izadi, Bluchestan Kerman-Hormozgan Razi-Iran <sup>37</sup>	2015	663	30-54 mo		-	-	94.6% <sup>c</sup>	-

a: One dose of MMR vaccine in addition to two dose MV at the age nine and 15 months.

b: Based on strict control of the vaccination administration technique and cold chain control by the researchers

c: two- doses of MMR at the ages of 12 and 18 months.

The reduced levels of measles- rubella antibodies in the post- vaccinated period may result in the accumulation of potentially susceptible individuals to measles and/or rubella in the community. Several reports have described significant rates of SVF in population with a sustained high rates of vaccination coverage and long absence of measles virus transmission<sup>(40-44)</sup>. In this regard, a prospective multicenter study performed by Smetana et al<sup>(43)</sup>, evaluated the measles IgG antibody concentrations among vaccinated subjects <sup>3</sup> 18 years. Of 1911 sera, 83.3% were seropositive. When different age groups were compared, the seroprevalence rate decreased overtime: (18-29 years: 81.1%, and 30-39 years: 61.5%). The results of a similar study in Korea, also indicated a progressive decline in antibodies as well as the avidity of antibodies over time in 2- to 30-year-old vaccinated persons <sup>(44)</sup>. Investigation of the measles outbreaks indicated the vaccine failure in 11- 49% of measles cases in several large outbreaks<sup>(11,54-57)</sup>. Also, in an epidemic<sup>(56)</sup>, up to 14% of cases had received at least two-doses of measles vaccine. These findings suggest SVF as the main cause of susceptibility which was mentioned earlier in group C and D of our study population. However, since the development of SVF was faster in these groups as compared to other studies, further investigations are recommended to evaluate the immunogenicity and long-term protection of measles vaccine in the Iranian population.

The WHO Regional Verification Commission of the Eastern Mediterranean region for measles and rubella elimination declared elimination of measles and rubella in Iran<sup>(31)</sup>. In the present study among 7- to 33 year- old individuals, who were vaccinated at least with two-doses of measles vaccine with different schedules, nearly 87% and 81% were seroprotected to measles and rubella respectively. Considering a 95% coverage rate with two-doses of vaccine, immunity rates of 83% and 77.6% were estimated in the population respectively. This level of immunity is less than what is necessary to prevent measles and rubella virus transmission in the community and achieve disease elimination (93%- 95% and 88-90% for measles and rubella respectively) <sup>(1, 6)</sup>. Also, phylogenetic analysis of the isolated measles viruses in the outbreaks of Iran showed major similarity with the measles viruses detected in neighbor countries. In some of these countries measles is still endemic<sup>(16,32)</sup>, which can be an alarming sign for Iran. Therefore further long-term prospective studies are recommended to evaluate the immunogenicity of MMR vaccine and investigate the persistence of seroimmunity. If the present study are confirmed in further studies, additional dose of MMR vaccine is required as a national/regional supplementary immunization activity program for the age group of 10-25 year old individuals to sustain measles-rubella elimination in Iran <sup>(38)</sup>.

One of the limitations of this study is the lack of information about the seroimmunity status after the primary vaccination which can differentiate between PVF and SVF. Also, the method used for the assessment of IgM response to revaccination may not be sensitive enough. Another limitation of this study is that it was not designed as a population based study, it was carried out in East of Mazandaran province, North of Iran with a modest number of participants which made the results less generalizable. Finally, there may be recall bias in group A regarding MR vaccination.

## Conclusion

Based on the findings, nearly 12.3% and 18.4% of fully vaccinated individuals aged 7- 33 years were seronegative to measles and rubella. The main causes of negativity to measles and rubella was SVF. The levels of seroprotection detected in this study was lower than what is required to achieve/maintain the elimination goals. To sustain measles and rubella elimination in Iran, further studies are recommended to assess the immunogenicity of the current MMR vaccine and strictly monitor the vaccine cold chain in all stages until use. Finally, periodic serosurveillance studies must be designed for different age groups in different provinces of Iran to detect gaps in the population immunity.

## Abbreviations

mMV: monovalent measles Vaccine, MV: measles Vaccine, MMR: Measles Mumps Rubella, EPI: Expanded program of Immunization, CRS: Congenital Rubella Syndrome, PVF: Primary Vaccine Failure, SVF: Secondary Vaccine Failure, WHO: world health organization, MAZUMS: Mazandaran University of Medical Sciences, TUMS: Tehran University of Medical Sciences ELISA: enzyme immune assay, IU/L: international unit/ liter. IgG: Immunoglobulin G, IgM: Immunoglobulin M, MCA: mean Concentration Antibodies.

## Declarations

**Ethic approval and Consent to Participate:** The study was provided ethical approval by the Mazandaran No: IR.MAZUMS. Rec.1396.3074 and Tehran IR.TUMS.IKHC. Rec.1399.075. The study obtained the consent of all participants and signed and informed consent form prior to the investigation. They were assured about confidentiality and that their contribution would be on a voluntary bases as well as that they had full rights to withdraw from the study at any time.

**Consent for Publication:** Not applicable

**Availability of data and materials:** obtained for this study will be available from the corresponding author at a reasonable request.

**Competing interests:** The authors declare that they have no competing interest

**Funding:** This study was funded by Vice-chancellor for research and Technology MAZUMS No: (IR.MAZUMS. Rec.1396.3074) and TUMS No: (IR.TUMS.IKHC. Rec.1399.075). The funders had no role in the design of study and collection, analysis, and interpretation and writing of manuscript.

**Authors Contributions:** HS and MK, A A, S S: involved in study design, literature search, and laboratory testing and writing the paper. M P, G G, MA: in Selection, recruiting, interviewing and blood sampling. MS participated in all study phases, (Conception, design, literature search, selection of eligible HCP, data collection and interpretation of the results writing the paper and finalizing the version to be published. All authors read and approved the final MS.



**Acknowledgment:** The researchers would like to thank the participated subjects and guardian for their participation in this study, and the health staff in the deputy of health for their help in recruiting personnel and blood sampling.

**Author's details:** HS and MK, A-R A, S S: Department of antimicrobial and clinical Pathology, IKHC, Teheran University of Medical Sciences, Tehran Iran. M-R P, G-R G, MA: all Deputy of Health, Roudaki Ave MAZUMS, Sari, Iran. MS: Pediatrics Infectious Diseases Research Center, Buali Hospital Pasdaran Bulv MAZUMS, Sari, Iran.

## References

1. World Health Organization. Measles vaccine: WHO position paper. April 2017. WKLY Epidemiol Rec. No 17. 2017;92:205-228.
2. World Health Organization. Measle. Key factsheet: 5 Dec 2019. [www.WHO.int/news-room/fact-sheet/detail/measles](http://www.WHO.int/news-room/fact-sheet/detail/measles).
3. Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, et al. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. *J Infect Dis*. 2004;189 Suppl 1:S116-22.
4. Perez SC, De Serres G, Bureau A, Skowronski DM Reduced Antibody Response to Infant Measles Vaccination: Effects Based on Type and Timing of the First Vaccine Dose Persist After the Second Dose. *Clin Infect Dis* 2017;65(7):1094-1102
5. Uzicanin A, Zimmerman L. Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. *J Infect Dis*. 2011;204 Suppl 1:S133-48.
6. Holzmann H, Hengel H, Tenbusch M, Doerr HW. Eradication of measles: remaining challenges. *Med Microbiol Immunol*. 2016;205(3):201-8.
7. Center for Disease Control and Prevention (CDC). Global Measles Outbreaks. [www.cdc.gov/global-health/measles/global-measles-outbreaks.html](http://www.cdc.gov/global-health/measles/global-measles-outbreaks.html).
8. Palamara MA, Visalli G, Picerno I, Di Pietro A, Puglisi G, et al. Measles outbreak from February to August 2017 in Messina, Italy. *J Prev Med Hyg*. 2018;59(1):E8-E13.
9. De Serres G, Markowski F, Toth E, Landry M, Auger D, Mercier M, et al. Largest measles epidemic in North America in a decade—Quebec, Canada, 2011: contribution of susceptibility, serendipity, and superspreading events. *J Infect Dis*. 2013;207(6):990-8.
10. Zipprich J, Winter K, Hacker J, Xia D, Watt J, Harriman K. Measles outbreak—California, December 2014–February 2015. *MMWR Morb Mortal Wkly Rep*. 2015;64(7):196.
11. Breakwell L, Moturi E, Helgenberger L, Gopalani SV, Hales C, et al. Measles Outbreak Associated with Vaccine Failure in Adults—Federated States of Micronesia, February–August 2014. *MMWR Morb Mortal Wkly Rep*. 2015;64(38):1088-92.
12. Nejati J, Sargolzaie N, Kiani M, Mahjoob M, Hashemi A. Measles epidemiology in sisthan and baluchistan province during April 2006–March 2011. *HEALTH SCOPE*. 2013;2 (1): 58-62.
13. Izadi S, Zahraie SM, Sartipi M. An investigation into a measles outbreak in southeast Iran. *Jpn J Infect Dis*. 2012;65(1):45-51.
14. Moghadam M, Afsarkazerooni P, Ebrahimi M, Soltani M, Razmpoor A, et al. Measles outbreak in South of Iran, where vaccine coverage was high: a case-series study. *Iran J Public Health*. 2014;43(3):375-80.
15. Karami M, Zahraei SM, Sabouri A, Soltanshahi R, Biderafsh A, et al. Documentation of Measles Elimination in Iran: Evidences from 2012 to 2014. *J Res Health Sci*. 2017;17(3):e00387.
16. Piri N, Karami M, Tapak L, Zahraei M, Mohammadi Y. Monitoring Progress towards the elimination of measles in Iran: supporting evidence from 2014 to 2016 by application of measles outbreaks data. *BMC Public Health*. 2019;19(1):687.
17. Lambert N, Strebel P, Orenstein W, Icenogle J, Poland GA. Lambert N, et al. Rubella. 2015;385(9984):2297-307.
18. Manteghi A. Changes in the epidemiology of measles due to mass-vaccination in Iran (1961-1971). *Iranian Journal of Public Health*, 1972;1(1):Abstract. <https://ijph.tums.ac.ir/index.php/ijph/article/view/1516>.
19. Shafiyi A, Mohammadi A. Measles vaccines in Iran: a 50-year review of vaccine development, production and effectiveness (1967-2017). *Jundishapur Journal of Microbiology*, 2018;11(5):e60725.
20. Saffar MJ, Ajami A, Pourfatemi F. An Immunological Study in the Pregnant women infected with Rubella virus in mazandaran province in 1999-2000. *Nameh Daneshgah (J. Mazandaran Univ of Med Scien*, 2001;11(3):1-6. (In Persian).
21. Azami M, Jaafari Z, Soleymani A, Badfar GH, Abbasalizadeh SH. Rubella Immunity in Pregnant Iranian Women: A Systematic Review and Meta-Analysis. *Int J Fertil Steril*. 2019;13(3):169-177.
22. Sadighi J, Eftekhari H, Mohammad K. Congenital rubella syndrome in Iran. *BMC Infect Dis*. 2005;5:44.
23. Zahraei SM, Gouya MM, Azad TM, Soltanshahi R, Sabouri A, et al. Successful control and impending elimination of measles in the Islamic Republic of Iran. *J Infect Dis*. 2011;204 Suppl 1:S305-11.
24. Pourabbas B, Ziyaeyan M, Alborzi A, Mardaneh J. Efficacy of measles and rubella vaccination one year after the nationwide campaign in Shiraz, Iran. *Int J Infect Dis*. 2008;12(1):43-6.
25. Yekta Z, Pourali R, Taravati MR, Shahabi S, Salary S, et al. Immune response to measles vaccine after mass vaccination in Urmia, Islamic Republic of Iran. *East Mediterr Health J*. 2009 May-Jun;15(3):516-25.
26. Honarvar B, Moghadami M, Moattari A, Emami A, Odoomi N, et al. Seroprevalence of anti-rubella and anti-measles IgG antibodies in pregnant women in Shiraz, Southern Iran: outcomes of a nationwide measles-rubella mass vaccination campaign. *PLoS One*. 2013;8(1):e55043.
27. Keshavarz M, Nicknam MH, Tebyanian M, Shahkarami MK, Izad M. Anti-rubella, Mumps and Measles IgG Antibodies in Medical Students of Tehran University, Iran. *J Allergy Asthma Immunology*. 2016;15(3):244-250.

28. Izadi S, S Zahraei, T Mokhtari-Azad. Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran. *HumVacci & Immunother* 2018;14(6):1412-6.
29. Karami M, Khazaei S, Zahraei SM, Mokhtari Azad T, Zahiri A, et al. Measles Outbreak in a Rural Population in Bahar District, Hamadan Province, West of Iran in 2018. *J Res Healt Scien*. 2020; 20(1): e00470.
30. Teleb N, Lebo E, Ahmed H, Hossam AR, El Sayed el T, et al. Progress toward measles elimination–Eastern Mediterranean Region, 2008-2012. *MMWR Morb Mortal Wkly Rep*. 2014 Jun 13;63(23):511-5.
31. Teleb N, Atta H, Hajjeh R. Measles and rubella elimination in the Eastern Mediterranean Region: successes and challenges. *East Mediterr Health J*. 2019;25(10):667-668.
32. Salimi V, Abbasi S, Zahraei SM, Fatemi-Nasab G, Adjaminezhad-Fard F, et al. Implementation of a national measles elimination program in Iran: Phylogenetic analysis of measles virus strains isolated during 2010-2012 outbreaks. *PLoS One*. 2014;9(4):e94846.
33. Emami Naeini A.R, Davarpanah M.A, Sherkat R., Karimi I, Hashemi J. Should We Consider another Booster Dose of Measles Vaccine? *IR J Med Scienc* 2002;27(1):1-3.
34. Yekta Z, Porali R, Taravati MR, Salary Sh, Khalily F, et al. Measles IgG sero-prevalence and its attributable factors in 5–25-year-old cases prior mass vaccination campaign in Urmia, northeastern Iran. *Iran Red Crescent Med J*. 2007; 9(1):e95867.
35. Saffar MJ, Alraza-Amiri M, Ajami A, Baba-Mahmoodi F, Khalilian A.R, et al. Measles seroepidemiology among adolescents and young adults: response to revaccination. *East Mediterr Health J* 2006;12(5):573-581.
36. Zamani A, Daneshjou K. Seroepidemiology of Measles in Primary School Students in Tehran, Iran. *Trends in Med Res* 2006;1(1)39-48.
37. Salimi V, Mokhtari-Azad T, Gooya MM, Hamkar R, Esteghamati AR, et al. Seroepidemiology of Measles in 5-25 year old age group before Measles/Rubella Mass Vaccination campaign in Tabriz (2003). *Med J Tabriz Unive Med Scien* 2006;28(2): 77-82 (In Persian).
38. Zahraei SM, Mokhtari-Azad T, Izadi S, Mohammadi M, Sabouri A. Seroprevalence of anti-rubella and anti-measles antibodies in women at the verge of marriage in Iran. *Vaccine*. 2020;38(2):235-241.
39. Carazo S , Billard MN , Boutin A, Serres GD. Effect of Age at Vaccination on the Measles Vaccine Effectiveness and Immunogenicity: Systematic Review and Meta-Analysis. *BMC Infect Dis*. 2020;20(1):251.
40. Karimi A, Arjomandi A, Alborzi A, Rasouli M, Kadivar MR, et al. Prevalence of measles antibody in children of different ages in Shiraz, Islamic Republic of Iran. *East Mediterr Health J*. 2004 Jul-Sep;10(4-5):468-73.
41. Kremer JR, Schneider F, Muller CP. Waning antibodies in measles and rubella vaccinees—a longitudinal study. *Vaccine*. 2006 Mar 24;24(14):2594-601.
42. Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I. Waning antibody levels and avidity: implications for MMR vaccine-induced protection. *J Infect Dis*. 2012;206(10):1542-8.
43. Smetana J, Chlibek R, Hanovcova I, Sosovickova R, Smetanova L, et al. Decreasing Seroprevalence of Measles Antibodies after Vaccination - Possible Gap in Measles Protection in Adults in the Czech Republic. *PLoS One*. 2017;12(1):e0170257.
44. Kang HJ, Han YW, Kim SJ, Kim YJ, Kim AR, et al. An increasing, potentially measles-susceptible population over time after vaccination in Korea. *Vaccine*. 2017;35(33):4126-4132.
45. Velicko I, Müller LL, Pebody R, Gergonne B, Aidryalieva C, et al. Nationwide measles epidemic in Ukraine: the effect of low vaccine effectiveness. *Vaccine*. 2008;26(52):6980-5.
46. Atrasheuskaya AV, Kulak MV, Neverov AA, Rubin S, Ignatyev GM. Measles Cases in Highly Vaccinated Population of Novosibirsk, Russia, 2000-2005. *Vaccine*. 2008;26(17):2111-8.
47. Saffar H, Saffar MJ, Saffar H. Vaccination in Developing Countries: A Review of Probable Factors for Lower Responses to Vaccine. *J Pediatr Rev*. 2013;1(1) 12-18.
48. Saffar MJ, Ajami A, Khalilian AR, Saffar H. The impact of maternal measles-rubella immunization on the 12-month-old infant's immune response to measles-mumps-rubella vaccine immunogenicity. *Eur J Clin Microbiol Infect Dis*. 2009;28(7):845-7.
49. Saffar MJ, Fathpour GR, Parsaei MR, Ajami A, Khalilian AR, et al. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes. *J Trop Pediatr*. 2011;57(5):347-51.
50. Shamsizadeh A, Nikfar R, Makvandi M, Hakimzadeh M, Alisamir, et al. Seroprevalence of measles, mumps and rubella Antibodies in 18 months and 6.5 years old children: 6 months after measles-mumps-rubella (MMR) vaccination. *Jundishapur J Microbiol*. 2012;5(4):578-581.
51. Rafiei Tabatabaei S, Esteghamati AR, Shiva F, Fallah F, Radmanesh R, et al. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children. *Arch Iran Med*. 2013;16(1):38-41.
52. Zahraei SM, Izadi S, Mokhtari-Azad T. Factors affecting the seroconversion rate of 12-month-old babies after the first injection of measles vaccine in the southeast of Iran. *Hum Vaccin Immunother*. 2016;12(12):3118-3124.
53. Izadi S, Mokhtari-Azad T, Zahraei SM. Measles vaccination coverage and seroprevalence of anti-measles antibody in south-east Islamic Republic of Iran. *East Mediterr Health J*. 2015;21(6):396-402.
54. Defay F, De Serres G, Skowronski DM, Boulianne N, Ouakki M, et al. Measles in children vaccinated with 2 doses of MMR. *Pediatrics*. 2013;132(5):e1126-33.
55. Cherry JD, Zahn M. Clinical Characteristics of Measles in Previously Vaccinated and Unvaccinated Patients in California. *Clin Infect Dis*. 2018;67(9):1315-1319.

56. Bernadou A, Astrugue C, Méchain M, Le Galliard V, Verdun-Esquer C, et al. Measles outbreak linked to insufficient vaccination coverage in Nouvelle-Aquitaine Region, France, October 2017 to July 2018. *Euro Surveill.* 2018;23(30):1800373.
57. De Serres G, Boulianne N, Defay F, Brousseau N, Benoît M, et al. Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12-14 months versus 15 months of age. *Clin Infect Dis.* 2012;55(3):394-402.